CYP2C19基因多态性及其对质子泵抑制剂疗效影响研究进展

[1] CYP2C19基因多态性对埃索美拉唑三联疗法根除幽门螺杆菌疗效的影响 [J]. 国际消化病杂志, 2011, 31 (03) : 177 - 180

[2] Improved Efficacy of Proton Pump Inhibitor – Amoxicillin – Clarithromycin Triple Therapy for Helicobacter pylori Eradication in Low Clarithromycin Resistance Areas or for Tailored Therapy[J] . Sanchai Prasertpetmanee,Varocha Mahachai,Ratha‐korn Vilaichone.Helicobacter . 2013 (4)

[3] Proton Pump Inhibitors in Pediatrics[J] . Robert M. Ward,Gregory L. Kearns.Pediatric Drugs . 2013 (2)

[4] Individualized Therapy for Gastroesophageal Reflux Disease[J] . Takahisa Furuta,Mitsushige Sugimoto,Naohito Shirai.Molecular Diagnosis & Therapy . 2012 (4)

[5] Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review[J] . Mitsushige Sugimoto,Jin Seok Jang,Yashiro Yoshizawa,Satoshi Osawa,Ken Sugimoto,Yoshihiko Sato,Takahisa Furuta,Ji Hyun Kim.Diagnostic and Therapeutic Endoscopy . 2012

[6] Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of H elicobacter pylori infection[J] . A. G. McNicholl,P. M. Linares,O. P. Nyssen,X. Calvet,J. P. Gisbert.Aliment Pharmacol Ther . 2012 (5)

[7] Efficacy of esomeprazole in treating acid-related diseases in Japanese populations[J] . Mitsushige Sugimoto,Takahisa Furuta.Clinical and Experimental Gastroenterology . 2012 (defa)

[8] Role of cytochrome P450 genotype in the steps toward personalized drug therapy[J] . Larisa Cavallari,Bress,Jeong.Pharmacogenomics and Personalized Medicine . 2011 (defa)

[9] Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement[J] . Circulation . 2010 (4)

[10] Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17[J] . AlainLi‐Wan‐Po,ThierryGirard,PeterFarndon,CandyCooley,JamesLithgow.British Journal of Clinical Pharmacology . 2010 (3)

[1] CYP2C19基因多态性对埃索美拉唑三联疗法根除幽门螺杆菌疗效的影响 [J]. 国际消化病杂志, 2011, 31 (03) : 177 - 180

[2] Improved Efficacy of Proton Pump Inhibitor – Amoxicillin – Clarithromycin Triple Therapy for Helicobacter pylori Eradication in Low Clarithromycin Resistance Areas or for Tailored Therapy[J] . Sanchai Prasertpetmanee,Varocha Mahachai,Ratha‐korn Vilaichone.Helicobacter . 2013 (4)

[3] Proton Pump Inhibitors in Pediatrics[J] . Robert M. Ward,Gregory L. Kearns.Pediatric Drugs . 2013 (2)

[4] Individualized Therapy for Gastroesophageal Reflux Disease[J] . Takahisa Furuta,Mitsushige Sugimoto,Naohito Shirai.Molecular Diagnosis & Therapy . 2012 (4)

[5] Proton Pump Inhibitor Therapy before and after Endoscopic Submucosal Dissection: A Review[J] . Mitsushige Sugimoto,Jin Seok Jang,Yashiro Yoshizawa,Satoshi Osawa,Ken Sugimoto,Yoshihiko Sato,Takahisa Furuta,Ji Hyun Kim.Diagnostic and Therapeutic Endoscopy . 2012

[6] Meta‐analysis: esomeprazole or rabeprazole vs. first‐generation pump inhibitors in the treatment of H elicobacter pylori infection[J] . A. G. McNicholl,P. M. Linares,O. P. Nyssen,X. Calvet,J. P. Gisbert.Aliment Pharmacol Ther . 2012 (5)

[7] Efficacy of esomeprazole in treating acid-related diseases in Japanese populations[J] . Mitsushige Sugimoto,Takahisa Furuta.Clinical and Experimental Gastroenterology . 2012 (defa)

[8] Role of cytochrome P450 genotype in the steps toward personalized drug therapy[J] . Larisa Cavallari,Bress,Jeong.Pharmacogenomics and Personalized Medicine . 2011 (defa)

[9] Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement[J] . Circulation . 2010 (4)

[10] Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17[J] . AlainLi‐Wan‐Po,ThierryGirard,PeterFarndon,CandyCooley,JamesLithgow.British Journal of Clinical Pharmacology . 2010 (3)